Canary Capital INJ Staking ETF Receives Nasdaq Listing Approval
Nasdaq approval for a Canary Capital Injective ETF introduces US investors to a listed product combining INJ exposure with staking rewards.
Nasdaq approval for a Canary Capital Injective ETF introduces US investors to a listed product combining INJ exposure with staking rewards. Injective (INJ) is trading at $8.05, down 1.5% since this brief published. This is an original TLT brief synthesising 2 outlets (Bitcoin Sistemi, TronWeekly), plus live market data, as of Fri, 06 Nov 2026 09:00:05 UTC.
The approval creates a potential Nasdaq-listed route for US investors to gain INJ exposure and participate in staking rewards, linking an altcoin ETF to network activity rather than price exposure alone.
- Canary Capital’s INJ ETF received Nasdaq approval, according to TronWeekly.
- Bitcoin Sistemi reported a roughly 6% INJ rise after the ETF news.
- Staking rewards are a central feature of the proposed product.
- INJ trades at $8.17, with a seven-day gain of 11.18%.
Bitcoin Sistemi and TronWeekly both connect the Nasdaq ETF development to Injective and say the product includes staking. Bitcoin Sistemi specifically reported that INJ gained approximately 6% following the news, while TronWeekly identified Canary Capital as the issuer and described the offering as regulated US exposure with staking rewards. The outlets do not contradict each other on the listing and staking features; their differences are emphasis, with TronWeekly adding the issuer name and Injective’s AI-infrastructure expansion, while Bitcoin Sistemi focuses on the reported price reaction.
- Injective’s staked INJ ETF earns Nasdaq listing approval
- Canary Capital INJ Staking ETF Receives Nasdaq Listing Approval — this brief
Two outlets reported that a staking-enabled 
Injective ETF is moving toward a Nasdaq listing. 
Bitcoin Sistemi said INJ rose approximately 6% after the ETF news, while TronWeekly reported that Canary Capital’s product received Nasdaq approval. The latter presents the development as a way for US investors to obtain regulated INJ exposure through an exchange-listed ETF.
TronWeekly said the Canary Capital ETF offers access to staking rewards, adding a yield-related feature to direct ownership of INJ. The same outlet also connected the development to Injective’s expansion into AI infrastructure, although neither outlet supplied further detail about that expansion or its relationship to the ETF. No launch date, fee, or other operating terms were specified in the supplied coverage.
The core account is corroborated across Bitcoin Sistemi and TronWeekly: the ETF is associated with Nasdaq, is focused on INJ, and includes staking. Their main difference is framing. Bitcoin Sistemi emphasized the immediate market reaction and placed the approximately 6% increase in the headline, whereas TronWeekly concentrated on Canary Capital, approval status, regulated US access and staking rewards. Neither outlet contradicted the other’s central claims.
Live market data show INJ at $8.17, down 0.32% over 24 hours but up 11.18% over seven days, alongside a $816.47 million market capitalization. The current decline does not directly conflict with Bitcoin Sistemi’s reported post-news rise because the supplied figures cover different periods. What to watch is whether Nasdaq listing details and operational staking terms become available, making the claimed investor access and reward mechanism concrete.
The wider crypto backdrop is cautious. Total market capitalization stands at $2.61 trillion, the overall market is broadly lower, and Bitcoin is down 6.00% over 24 hours. The Fear & Greed index reads 28, placing sentiment in the “Fear” range. Against that backdrop, the ETF approval introduces a distinct US access channel for INJ, while the later availability of product terms will determine how staking rewards and exposure are implemented.
Since this brief published about 2 hours ago, Injective (INJ) has moved from $8.17 to $8.05 — -1.47%.
The chart plots INJ's price: grey is the move before this brief published, the vertical dashed line marks the moment it published, the horizontal dashed line is the price then, and the coloured area is the move since — from TLT's market data (daily resolution). It shows what happened after the news, not that the news caused it; many factors move prices. Not financial advice.
At today's peer-to-peer rate, 1 INJ ≈ ₦11,116.29 (about $8.05), down 4.2% over 24 hours. The naira itself trades about 2.4% above the official rate on the P2P market, so a Nigerian buyer's effective cost differs from the headline dollar price.
Live market data
Current prices for the asset in this story — live, source-stamped, updated every 15 minutes.
Canary Capital INJ Staking ETF Receives Nasdaq Listing Appro — questions & answers
Who is behind the proposed INJ staking ETF?
TronWeekly identified Canary Capital as the issuer of the ETF that received Nasdaq approval.
What distinguishes the proposed INJ ETF?
Both outlets describe a Nasdaq-listed product providing INJ exposure with staking included. TronWeekly also highlighted regulated access for US investors.
How is INJ trading after the ETF news?
Bitcoin Sistemi reported an approximately 6% rise immediately after the announcement. Current data show INJ at $8.17, down 0.32% over 24 hours but up 11.18% over seven days.
How much is 1 Injective worth in naira today?
About ₦11,116.29 at the live peer-to-peer (P2P) USDT rate, which is what Nigerians typically trade at — equivalent to roughly $8.05. The naira price moves with both INJ's US-dollar price and the USDT/NGN rate; use our Injective in naira page for any amount.
Has Injective's price moved since this brief was published?
INJ is down 1.47% since this brief first published — trading at $8.05 now versus $8.17 at publication. TLT re-checks this figure against CoinGecko and Binance every 15 minutes.
Which outlets reported this story?
This is an original TLT brief that synthesises reporting from Bitcoin Sistemi, TronWeekly, with the key figures cross-checked for agreement across them. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original TLT brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.